GSK DREAMM-3 phase III trial for Blenrep did not meet its primary endpoint

GSK DREAMM-3 phase III trial for Blenrep did not meet its primary endpoint

Related Keywords

,Kyowa Kirin Group ,Biowa Inc ,Drug Administration ,Seagen Inc ,Multiple Myeloma ,Kyowa Kirin ,